Home

Dok2 (human)

Overview Dok2 a member of the p62dok family of proteins that interact with receptor tyrosine kinases and mediate particular biological responses. Constitutively tyrosine phosphorylated in hematopoietic progenitors isolated from chronic myelogenous leukemia (CML) patients in the chronic phase. It may be a critical substrate for p210(bcr/Abl), a chimeric protein whose presence is associated with CML. Contains a pleckstrin homology domain at the amino terminus, 13 potential tyrosine phosphorylation sites, and six PXXP SH3 recognition motifs. Binds p120 (RasGAP) from CML cells. Note: This description may include information from UniProtKB. Protein type: Adaptor/scaffold Cellular Component: cytosol Molecular Function: receptor signaling protein activity; phospholipid binding; transmembrane receptor protein tyrosine kinase adaptor protein activity; insulin receptor binding Biological Process: cell surface receptor linked signal transduction; Ras protein signal transduction; blood coagulation; signal transduction; leukocyte migration Reference #:  O60496 (UniProtKB) Alt. Names/Synonyms: Docking protein 2; docking protein 2, 56kDa; DOK2; Downstream of tyrosine kinase 2; p56(dok-2); p56DOK; p56dok-2 Gene Symbols: DOK2 Molecular weight: 45,379 Da Basal Isoelectric point: 5.78  Predict pI for various phosphorylation states CST Pathways:  ErbB/HER Signaling Protein-Specific Antibodies or siRNAs from Cell Signaling Technology®

Select Structure to View Below Dok2 2D9W - A=1-116 (human) 2DLW - A=153-247 (human)

STRING  |  Scansite  |  Phospho.ELM  |  NetworKIN  |  Pfam  |  RCSB PDB 2D9W 2DLW  |  Phospho3D  |  DISEASE  |  Source  |  InnateDB  |  UCSD-Nature  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene

	Sites Implicated In
molecular association, regulation: Y139‑p

	Modification Sites and Domains	Show Modification Legend
Click here to view phosphorylation modifications only

	Modification Sites in Parent Protein, Orthologs, and Isoforms	Show Modification Legend

SS  SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.	MS  MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.			human
0	1		K7-u	_MGDGAVkQGFLyLQ
0	1		Y12-p	AVkQGFLyLQQQQTF
0	3		S34	GASLYGGSDCALARL
0	3		L121	FPGQRKELsGPEGKQ
0	1		S122-p	PGQRKELsGPEGKQs
0	1		S129-p	sGPEGKQsRPCMEEN
1	108		Y139-p	CMEENELyssAVtVG
0	2		S140-p	MEENELyssAVtVGP
0	3		S141-p	EENELyssAVtVGPH
0	1		T144-p	ELyssAVtVGPHKEF
0	1		Y170-p	RCHLRGSyTLRAGES
0	1		T189-p	WGGPEPGtQLyDWPY
0	31		Y192-p	PEPGtQLyDWPYRFL
0	1		S269-p	ASLPRPDsPySRPHD
3	1		Y271-p	LPRPDsPySRPHDsL
0	1		S277-p	PySRPHDsLPPPsPT
0	1		S282-p	HDsLPPPsPTTPVPA
3	782		Y299-p	PRGQEGEyAVPFDAV
0	2		S309-p	PFDAVARsLGKNFRG
0	15		Y330-p	QLLADPLyDsIEEtL
0	5		S332-p	LADPLyDsIEEtLPP
0	6		T336-p	LyDsIEEtLPPRPDH
6	25		Y345-p	PPRPDHIyDEPEGVA
0	123		Y357-p	GVAALSLyDSPQEPR
1	41		Y402-p	GWQPGTEyDNVVLKK

	mouse
K10	RMEEPAVKQGFLHLQ
H15	AVKQGFLHLQQQQTF
S37-p	AAVLYGEsGCALARL
S124-p	FPGQRKGsPGLEEKS
P125	PGQRKGsPGLEEKSG
G132	PGLEEKSGSPCMEEN
Y142-p	CMEENELySSSTTGL
S143	MEENELySSSTTGLC
S144	EENELySSSTTGLCK
T146	NELySSSTTGLCKEY
Y172	RCRLRGSYTLRTGVS
T191	WGGPEPGTQLYDWPY
Y194	PEPGTQLYDWPYRFL
S274	TVLPRPESPySRPHD
Y276-p	LPRPESPySRPHDSL
S282	PySRPHDSLPSPSPG
S287	HDSLPSPSPGTLVPG
Y304-p	PGAPEGEyAVPFDTV
S314	PFDTVAHSLRKSFRG
Y335	PHLPDPLYDSIQEDP
S337	LPDPLYDSIQEDPGA
D341	LYDSIQEDPGAPLPD
Y351-p	APLPDHIyDEPEGVA
Y363	GVAALSLYDRTQRPS
Y402-p	DWPQATEyDNVILKK

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E Produced by 3rd Millennium  |  Design by Digizyme ©2003-2013 Cell Signaling Technology, Inc.